Endocrine Therapy for Leptomeningeal Metastases from ER-Positive Breast Cancer: Case Report and a Review of the Literature

Breast J. 2016 Mar-Apr;22(2):218-23. doi: 10.1111/tbj.12554. Epub 2016 Jan 8.

Abstract

Leptomeningeal disease is an uncommon complication of estrogen receptor positive breast cancer. While there is little consensus on the standard of care, recommendations from current clinical practice guidelines are to treat with intrathecal chemotherapy, necessitating invasive procedures and potentially resulting in a substantial incidence of serious complications and side effects. Here, we review all published evidence of the effectiveness of systemic hormonal therapy alone in treating this condition, with the advantage of requiring no invasive procedures and having virtually no serious complications or side effects. Evidence indicates that most hormonal therapies can penetrate the central nervous system and can be an effective treatment of endocrine sensitive breast cancer that is widely metastatic to the leptomeninges.

Keywords: ER-positive; breast cancer; endocrine therapy; leptomeningeal.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology*
  • Female
  • Humans
  • Meningeal Neoplasms / drug therapy*
  • Meningeal Neoplasms / secondary*
  • Middle Aged
  • Receptors, Estrogen / metabolism

Substances

  • Antineoplastic Agents, Hormonal
  • Receptors, Estrogen